Kyntheum (Brodalumab)

Brodalumab is a fully human monoclonal antibody that binds to the interleukin‑17 receptor A, blocking signaling from several IL‑17 cytokines. This inhibition suppresses downstream inflammatory cascades, decreasing keratinocyte proliferation and immune cell recruitment in psoriatic lesions.

The dosing regimen for Kyntheum is determined by the prescribing healthcare professional based on the patient’s disease severity, response, and clinical guidelines. The prescriber selects the appropriate dose and administration schedule, which is administered by subcutaneous injection in a clinical setting.

The safety of brodalumab during pregnancy or lactation has not been established. It is classified as contraindicated unless the potential benefit outweighs the risk, and clinicians should discuss potential risks with patients and consider alternative therapies when appropriate.

To request Kyntheum, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Compared with other IL‑17 inhibitors, brodalumab uniquely blocks the IL‑17 receptor A, inhibiting multiple IL‑17 cytokines simultaneously. This broader blockade can result in rapid skin clearance, though safety profiles differ; clinicians consider efficacy, dosing frequency, and individual patient risk when selecting therapy.

Kyntheum must be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame specified by the manufacturer.

Kyntheum is supplied as a sterile subcutaneous solution for injection. It is administered by a healthcare professional using a pre‑filled syringe or autoinjector, typically in the abdomen, thigh, or upper arm, following aseptic technique and according to the prescribed dosing schedule.

The most serious risks include the potential for suicidal ideation or behavior, serious infections such as cellulitis or pneumonia, and neutropenia. Patients should be closely monitored for mood changes, signs of infection, and blood count abnormalities throughout treatment.

Kyntheum is contraindicated in patients with active serious infections, known hypersensitivity to brodalumab or any excipients, and should be avoided in individuals with a history of suicidal behavior unless closely monitored. Caution is also advised for patients with inflammatory bowel disease or those receiving live vaccines.